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In a randomized clinical trial, it is often necessary to recruit subjects at
multiple study centers to accrue enough sample size within an acceptable period
of time and to enhance the generalizability of study results. However, there might
be factors that vary by center, which exert influence on the study’s outcomes.
These factors include patient characteristics and medical practice patterns. Such
center effects potentially lead to dependence between outcomes at each center.
In addition to factors that vary by center, heterogeneity between trials may arise
from the treatment effect itself. That is, the treatment may have worked better
in some centers than others. Such treatment-by-trial interaction heterogeneity
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can be accounted for by using random interaction effects between the treatment
and trial in a random effect model. If these effects are sufficiently large, a model
which ignores the center effect or the treatment-by-center effect may lead to in-
correct inference.
When the primary endpoint of interest in the study is the time it takes for
a certain event to occur (time-to-event), a proportional hazards model with ran-
dom effects which includes the treatment-by-center interaction term as well as
the baseline risk term can be used [1]. Another alternative to analyze this kind
of data is meta-analysis in terms survival-analysis models fitted to data for the
individual centers.
Meta-analysis is defined as the statistical analysis of a large collection of anal-
ysis results from individual studies for the purpose of integrating the findings [12].
The objectives of a meta-analysis include increasing power to detect an overall
treatment effect, estimation of the degree of benefit associated with a particu-
lar study treatment, assessment of the amount of variability between studies, or
identification of study characteristics associated with particularly effective treat-
ments. When several studies have conflicting conclusions, a meta-analysis can
be used to estimate an average effect or to identify a subset of studies associated
with a beneficial effect. In meta-analysis, variation between centers can be cap-
tured using a random effects model [3, 4, 13]. As indicated in [4], meta-analysis
includes the following basic steps:
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Identification of literature: Meta-analysis needs to find all of the relevant
articles on the topic. Sources to be searched include the published literature, un-
published literature, dissertations and drug company studies. Including all trials
which could potentially contribute to the meta-analysis minimizes problems asso-
ciated with selection or publication bias [4, 13, 23]. Although, in general it is true
that meta-analysis needs to find all relevant articles on the topic, a multi-center
clinical trial will have been designed prospectively with a combined analysis of
the data from all centers as its main objective and a meta-analysis can be used
[13]. Individual centers are expected to follow a common protocol.
Study selection: Once the author of a meta-analysis has assembled a large
number of studies, it is important to select studies based on eligibility criteria
used in accepting or rejecting a study. The criteria include whether the study
includes enough information for analysis (a point estimate and a standard devia-
tion or standard error), year and demographic features of the study, study design
(observational or randomized), treatment dose, and sample size.
Data extraction: After identifying an appropriate group of studies, the re-
searcher has to extract the relevant data from each study. There are many sources
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of potential error in data extraction, such as misinterpreting tables and data en-
try.
Statistical analysis: In meta-analysis the type of model to be used should be
specified. The type of model (fixed effects versus random effects) to be used is
specified based on the degree of heterogeneity of between-study variability of the
collected studies. To determine the degree of heterogeneity, a chi-square test is
often used [4]. A fixed effect model assumes that the parameter measuring treat-
ment difference is the same across all trials. A random effects model assumes
this parameter acts as a random variable taking different values from one trial
to the next. More discussion about meta-analysis models including parameter
estimation methods is given in Chapter 3.
1.2 Motivation
In this thesis research we use a multi-center study and investigate the
overall treatment effect using two approaches, the first a unified parametric pro-
portional hazards model and the second a meta-analysis model. We use a dataset
from a multi-center clinical trial EST 1582 in small-cell lung cancer conducted
by the Eastern Cooperative Oncology Group (ECOG). Previous studies on this
dataset have shown that there is significant variation in treatment effect by center
[9, 10]. Thus, in the unified parametric proportional hazards model we include
4
random effects for both the treatment-by-center interaction and for baseline risk.
In the meta-analysis model, we assume the studies in separate centers are in-
dependent, and we take from each center the minimum information that might
be published in a journal article (center treatment effect estimate and standard
error). We use a meta-analysis random effects model to account for the hetero-
geneity of treatment effects among centers, beyond the variation accounted for
by fixed effects. In this thesis we are motivated to see how the overall treatment
effect estimate varies from the two models: the meta-analysis random effects
model and the unified parametric proportional hazards model with both center
and treatment-by-center random effects. We have been unable to find any pre-
vious study that used patient level data and analyzed using both unified and
meta-analysis to investigate what could go wrong in the meta-analysis.
1.3 Multi-center data: example
The ECOG EST 1582 study compares two different chemotherapy reg-
imens: a standard therapy consisting of cyclophosphamide, adriamycin and vin-
cristine (CAV) and an alternating regimen (CAV-HEM) where cycles of CAV
were alternated with HEM (hexamethylmelamine, etoposide and methotrexate).
Gray ([9] and [10]) has made a detailed analysis of institutional variation in this
dataset and has shown the variation of treatment effect by center. In Chapter
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4, we use these data to investigate the center effects using a unified parametric
proportional hazards model and a random effects meta-analysis model.
1.4 Survival proportional hazards model with
random effects
Let i be a cluster, i = 1, . . . , g, and let j index subjects in cluster i,
j = 1, . . . , ni. Let Zij be a random death time and let Cij be the corresponding
right-censoring time for subject j in cluster i . We assume that the censoring
times are independent of the survival times and that Tij = min(Zij, Cij), and
δij = I[Zij≤Cij ] are observed rather than Zij, Cij. Each patient will have a binary
variable Xij1 representing the treatment group to which the patient is randomized
(Xij1 = 0 if a patient is in the control group and Xij1 = 1 if the patient is in the
treatment group). The proportional hazards model with random center effects
ui and random treatment-by-center interaction vi is given as
hij(t|ui, vi) = h0(t) exp
( p∑
k=1
Xijkβk + ui + viXij1
)
(1.1)
ui ∼ N(0, σ2), vi ∼ N(0, τ 2), cov(ui, vi) = 0
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where h0(t) is the baseline hazard function, β is the fixed effects vector of dimen-
sion p, and Xij is the vector of covariates. The variance σ
2 of the ui represents the
heterogeneity between centers of the overall underling baseline risk and the vari-
ance τ 2 of vi represents the heterogeneity between centers of the overall treatment
effect β1. More discussion about this model and other survival proportional haz-
ards models, in which h0(t) is known except for a finite-dimensional parameter,
is given in Chapter 2.
1.5 Meta-analysis random effects model
Let θ be the central parameter of interest and assume there are i =
1, 2, . . . , g independent studies. Assume that Yi is such that E(Yi) = θ and
let s2i = var(Yi) be the variance of the summary statistic in the ith study. The
random effects model assumes each study is associated with a different but related
parameter. It postulates that each study summary statistic, Yi, is drawn from a




indep.∼ N(θi, s2i ) (1.2)
Furthermore, each study-specific mean, θi, is assumed to be drawn from some
superpopulation of effects with θ and variance τ , with θi|θ, τ 2
indep.∼ N(θ, τ 2). θ and
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τ represent, respectively, the average treatment effect and inter-study variation.
Although s2i are assumed known, in reality the the estimated variance of θi,
var(θi), is treated as if it were the true variance s
2
i . Details of this model and the
fixed effects meta-analysis model are given in Chapter 3.
1.6 Objective of the study
The objective of this study is to investigate the validity of overall treat-
ment effects estimates from meta-analysis. We do this by comparing treatment
effects estimate from a meta-analysis model and a unified parametric proportional
hazards model. In the meta-analysis, we use a random effect model to capture
center variation and treatment-by-center variation. In the unified parametric
proportional hazards model, we include a center random effect and treatment-
by-center random effect. We study the bias and the mean square errors of the
estimates from the two models. The thesis includes results of data analysis from
a multi-center clinical trial and from a simulation study. In the simulation study,
we vary the design matrix and the degree of center-by-treatment random effect
and compare the treatment effects estimate from the two models.
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1.7 Organization of the thesis
This thesis is organized as follows: Chapter 2 gives a brief review of
survival proportional hazards models. It includes data classifications, basic quan-
tities, development of a parametric proportional hazards model, and estimation
methods. Chapter 3 discusses meta-analysis models and estimation methods.
Chapter 4 reviews the ECOG data from Gray’s paper and presents the results
from the survival analysis and meta-analysis models discussed in Chapter 2 and
3. Chapter 5 presents simulation results. Chapter 6 presents a discussion and





In Section 2.1 we explain survival data structure and the basic parameters
that are used in modeling survival data. In Section 2.2 we define the proportional
hazards model. First, we define the general model; then we show the presence
of random effects in the model. Finally, we show how we use the NLMIXED
procedure in SAS to get parameter estimates.
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2.1 Survival data and basic quantities
Many types of non-life data, as well as some life data, are complete or
fully observed. In many cases, life data contains uncertainty as to when exactly
an event happened (i.e., when the unit failed). Data containing such uncertainty
as to exactly when the event happened are termed censored data. There are at
least three types of possible censoring schemes, right, left and interval censoring.
Right censoring is the most common type of censoring. For right censored data
all that is known for some individuals is a time beyond which the subject is still
alive. In the second type of censoring, left censoring, a failure time is only known
to be before a certain time. Interval censoring data reflects uncertainty as to the
exact time the units failed within an interval [16, 17, 21].
The two basic quantities used in modeling survival data are the survival func-
tion and the hazard rate function. Let T denote a continuous non-negative ran-
dom survival time, with probability density function f(t) and cumulative distri-
bution function F (t) = Pr(T ≤ t). The survival function is the probability of an
individual surviving beyond time t. It is defined as
S(t) = Pr(T > t). (2.1)
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The hazard function, which is also called the hazard rate or conditional failure





The cumulative hazard function, H(t), is the accumulation of the hazard up to
time t; that is, H(t) =
∫ t
0 h(u)du. The survival function and the cumulative
hazard function are related through the identity S(t) = exp{−H(t)}.
2.2 Parametric proportional hazards models
The proportional hazards model is the most popular model in sur-
vival data analysis. It relates the underlying hazard function, describing haz-
ard changes over time, to the effect parameters, describing how hazard relates
to other factors. The proportional hazards assumption is the assumption that
non-time-dependent effect parameters multiply the time-dependent hazard. The
effect parameters specified by the proportional hazards model can be reported as
log hazard ratios for population members with specified covariate values differing
by a unit amount. For the simplest case of treated and control, the proportional
hazards model states that the hazard of treated subject over the hazard of control
subject does not change over time [6, 16]. In general the proportional hazards
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model can be written as
hi(t) = h0(t) exp(X
tr
i β) (2.3)
where h0(t) is the baseline hazard function corresponding to the hazard function
of a subject with covariate information Xi equal to 0 and X
tr
i is the transpose of
the vector Xi.
The baseline hazard function h0(t) either can be assumed to have a particular
parametric form or can be left unspecified. In parametric proportional hazards
models, we assume a particular parametric function for the baseline hazard h0(t).




with λ > 0, ρ > 0. The scale parameter1 λ provides information on the way
the hazard (or density) is stretched out over time, and the shape parameter ρ
parameterizes a variety of shapes for the density.
When ρ is smaller than 1, the hazard decreases monotonically with time.
However, when ρ is larger than 1, the hazard increases monotonically with time.
When ρ is equal to 1, this hazard (2.4) is the exponential hazard and is constant
1In this thesis we use λ as the scale parameter, but some people use λ−1/ρ as the scale
parameter.
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over time. For a fixed value of λ, ρ determines how fast the hazard function
increases (ρ > 1) or decreases (ρ < 1)
Substituting h0(t) from (2.4) into (2.3), we get
hi(t) = λρt
ρ−1 exp(X tri β) (2.5)





λρsρ−1 exp(X tri β)ds) = exp(−λtρ exp(X tri β)) (2.6)
and
fi(t) = hi(t)Si(t) = λρt
ρ−1 exp(X tri β) exp(−λtρ exp(X tri β)) (2.7)
The random survival time Ti with this density has a Weibull distribution, de-
noted as Ti ∼ Weib(λ exp(X tri β), ρ). Thus all subjects following model (2.5) are
Weibull distributed with the same shape parameter ρ but differ with respect to
the scale parameter.
Other kinds of distributions that can be used instead of the Weibull include
Gamma, lognormal, loglogistic, normal, and Gompertz. Details of these choices
can be seen in survival analysis books such as the one by Klein and Moeschberger
[16]. When the baseline hazard h0(t) in (2.3) is left unspecified, it has one para-
metric factor, X tri β, and one factor which is not specified in a parametric way,
h0(t), and we call the model semiparametric [6].
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In survival data analysis, situations where survival times are not independent
are frequently encountered. Such data tends to arise when different individuals
have some features in common. An example of such data arises in a multi-center
study, in which the survival experience of individuals from the same center may
be more similar than that for individuals from different centers. In this kind of
situation, we might represent the effect of the center by introducing a random ef-
fect in the model. In survival data analysis, a random effect is often referred to as
a frailty [7, 17]. A frailty model is a random effect model for time-to-event data,
where the random effect (the frailty) has a multiplicative effect on the baseline
hazard function. The most common model for frailty is the shared frailty model
where subjects in the same cluster all share the same frailty factor [8, 10, 17,22].
The shared frailty model is defined as
hij(t) = h0(t) exp(X
tr
ij β + ui) (2.8)
where hij(t) is the conditional hazard function for the j
th subject from the ith
cluster, h0(t) is the baseline hazard, β is the fixed effects vector of dimension p,
Xij is the vector of covariates, and ui is the logarithm of the shared multiplicative
frailty parameter for the ith cluster. The model can be written as




where wi = exp(ui) is the frailty for the i
th cluster. We see that individuals in a
group i with wi > 1 are frail (high risk) and individuals in a group i with wi < 1
are strong (lower risk). The wi are an independent and identically distributed
sample from a distribution with mean 1 and some unknown variance. A math-
ematically convenient choice for the distribution of the wi is the one-parameter




where Γ denotes the gamma function. With this frailty distribution, the mean
of W is 1 and the variance of W is θ, so that large values of θ reflect a greater
degree of heterogeneity among groups and a stronger association within groups.
Model (2.8) is a single frailty model, where there is only one random term.
Next we discuss a model where there are two random terms within the same
cluster. A typical example of such a model is a multi-center clinical trial with a
frailty term describing the heterogeneity between centers and a second random
term modeling the center-by-treatment interaction. The second random effect
term describes the treatment heterogeneity between centers [1, 2, 17]. In this
situation a model with two random effects shown in (1.1) can be used. That is
hij(t|ui, vi) = h0(t) exp(
p∑
k=1
Xijkβk + ui + viXij1).
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One factor limiting the practical use of models with random terms is the lack
of a good estimation method. The two approaches used in practice are the EM
algorithm, which treats the frailties as missing values, and the partial penalized
likelihood (PPL) approach, which considers the density of the frailty as a penalty
term in the likelihood.
Another technique of likelihood based analysis of random effect survival data is
to use numerical integration of the random effects based on Gaussian quadrature
[14]. This technique can be implemented in SAS using the NLMIXED procedure
[15]. For the review of the first two methods (EM algorithm approach and PPL
approach) and detailed discussion about the numerical integration of the random
effects based on Gaussian quadrature, see Liu and Huang [14]. In this paper we
use numerical integration, allowing multiple random effects in the random state-
ment in the NLMIXED procedure. The complete code to analyze the ECOG
lung cancer data using model (1.1) is given in the data analysis section.
PROC NLMIXED fits by maximizing an approximation to the likelihood in-
tegrated over the random effects using adaptive Gaussian quadrature integral
approximation. The Dual quasi-Newton algorithm is the default optimization
technique. Other integral approximation methods and optimization techniques
can be specified. PROC NLMIXED gives parameter estimates along with their
approximate standard errors based on the second derivative matrix of the like-
lihood function. Approximate standard errors are computed using the delta
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method. NLMIXED can be used to analyze data that are normal, binomial,
or Poisson or that have any likelihood programmable with SAS statements. In
the model statement, the conditional distribution of the data given the random
effects should be specified. One possibility is to use ‘general(ll)’ which specifies a
general log likelihood function constructed using SAS programming statements.
The random statement defines the random effects and their distribution. The
only available distribution for the random effects is normal(m,v) with mean m
and variance v. The syntax can be written as:
random u ~ normal(0,s2u) subject=study;
where subject specifies the clusters. When two effects are present as in (1.1),
they can be specified as follows
random b1 b2 ~ normal([0,0],[g11,g21,g22]) subject=study;
where [g11,g21,g22] is the lower triangle of the random-effects variance matrix




As mentioned in the Introduction, meta-analysis involves combining summary
information from related but independent studies. In combining information from
different trials, one should consider two possible types of models, fixed effects and
random effects models. In a fixed effects model, the true treatment difference is
considered to be the same for all trials. The standard error of each trial estimate
is based on the variation of the sample within the trial. In a random effects model,
the true treatment difference in each trial is itself assumed to be a realization of
a random variable, which is usually assumed to be normally distributed [3, 4, 5].
In Section 3.1, estimation of the treatment difference in an individual trial is
discussed. In Section 3.2, the meta-analysis fixed effects model and the random
effects model are reviewed. A likelihood approach to the estimation of parameters
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and its implementation in PROC MIXED in SAS is shown.
3.1 Estimating the treatment difference in an
individual trial
Often the meta-analyst has little control over the choice of the summary
measure because most of the decision is dictated by what was employed in the
primary studies [4]. Meta-analysis may be performed on studies for which the
available data are in the form of summary information from trial reports or
publications or on studies for which individual patient data are available. The
form of the data available from each study has implications for the meta-analysis.
Three forms are commonly encountered [4, 13]. The first consists of an estimate of
the treatment difference and its variance or standard error, which is the minimum
amount of information needed. The second form of data is slightly more detailed,
consisting of summary statistics for each treatment group, enabling a choice to
be made between several different parameterizations of the treatment difference.
The third form, individual patient data, allows the most flexibility. In this case it
is possible to choose any sensible parametrization of the treatment difference and
the method of estimation. In addition, if all the studies provide individual patient
data, a more thorough analysis can be undertaken by employing a statistical
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modeling approach. In this section, we describe the estimation of the treatment
difference from an individual study for survival data. Estimation of the treatment
difference for other kinds of data in an individual study, including binary data
and normally distributed data, is described in [4, 13].
A model in survival analysis is expressed in terms of the hazard function or
the survivor function. The hazard function is the limiting probability per unit
time in which the event occurs, conditional on survival until time t. The survivor
function is the probability that the event occurs after time t. Let hT (t|1) and
hT (t|0) represent the hazard functions for the treated and control groups and
ST (t|1) and ST (t|0) their respective survivor functions. Assume the proportional
hazards model under which hT (t|1) = exp(θX)hT (t|0) for all t. The treatment







3.2 Fixed and random effects models
3.2.1 Fixed study effects model
The fixed-effects model assumes each study measures the same underlying pa-
rameter and that there is no inter-study variation. Let θ be the central parameter
21
of interest and assume there are i = 1, 2, . . . , g independent studies. Let θ̂i be an
estimate of θ from the ith study. The fixed effects model is given by
θ̂i = θ + εi, (3.2)
where the εi are the error terms and are realizations of normally distributed
random variables with expected value 0 and variance ξ2i assumed known. That is
θ̂i ∼ N(θ, ξ2i ).
Although ξ2i are assumed known, in reality the estimated variance of θi,
var(θi), is treated as if it were the true variance ξ
2
i , that is, no allowance is
made for the error in the calculated term var(θi). Let wi = 1/ξ
2
i . When ξ
2
i is





3.2.2 Random study effects model
In a random effects model, it is assumed that the treatment difference parame-
ters in the g studies are a sample of independent observations from an underlying
distribution. In real situations, the underlying distribution is not known. If the
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underlying distribution is normal, then it is completely described by its mean
and its variance. In this paper, we restrict the underlying distribution to nor-
mally distributed random effects with mean θ and unknown variance τ 2 (i.e.,
θ̂i
indep.∼ N(θ, τ 2)). It is important to note that, when the log-hazard ratio (3.1) is
used for center treatment difference, the center-to-center variation is not due to
the baseline risk difference between the centers but is due to treatment-by-center
variation. This is because the baseline risk affects the hazard rates of both the
treated group and control group in the same way, in particular in the same direc-
tion (decrease or increase); the log-hazard ratio remains unaffected. In general
the random study effects model is given by
θ̂i = θ + vi + εi, (3.4)
for i = 1, 2, ..., g, where the vi are normally distributed random effects with
mean 0 and variance τ 2. The terms vi and εi are assumed to be independently
distributed. It follows that
θ̂i ∼ N(θ, ξ2i + τ 2).
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If both ξ2i and τ
2 are assumed known, the maximum likelihood (MLE) of θ,









In reality, τ 2 is unknown and statistical methods are used to estimate it from
data, either by a likelihood or a Bayesian approach. Here we discuss the likelihood
approach and its implementation in SAS PROC MIXED. A Bayesian method can
be seen in [4].
Assuming w−1i = ξ
2
i is known, the contribution to the likelihood function from
study i is











The likelihood function is given by the product of the individual study likelihood
functions, and the log-likelihood function is given by














Maximum likelihood estimates of τ 2 and θ can be found through an iterative
scheme. Each iteration involves two steps: first τ 2 is treated as fixed and the
value of θ, which maximizes the log-likelihood, is calculated. Then θ is treated
as fixed and the value of τ 2, which maximizes the log-likelihood, is calculated.
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2 and τ̂ 2M,t is the ML estimate of τ
2 at
the tth cycle of the iteration.











An initial estimate of τ 2, τ̂ 2M,0, can be obtained using the method of moments to
start the iteration process [13].
The maximum likelihood estimator of τ 2 does not take into account the in-
formation used in estimating θ, and, thus, will usually underestimate [13]. We
follow [13] (page 94 to 96) in describing the alternative estimation steps lead-
ing to REML estimates in the model (3.4), which takes account of this loss of
information. The REML log-likelihood function is based on the residual term
(θ̂i − θ̂∗t+1), instead of the observation θ̂i, and given by
lR(τ

























REML estimates are found via a similar iterative scheme to that described





−1. At the (t + 1)th cycle of the iteration,
(3.6) is used to calculate an updated estimate of θ. The REML estimate of the













3.3 SAS statements for meta-analysis
The ML and REML estimates can be found using PROC MIXED pro-
cedure in SAS. As indicated in [13], the following steps are needed to get REML
estimates; first we need to create a diagonal variance matrix with the estimated
within-study variance components as the diagonal elements. To do this, suppose
that the values of i, θi,wi have been entered into the dataset ‘temp’ under the
variable names ‘study’, ‘survtime’, and ‘w ’ respectively. Then the following code







Then we use the following PROC MIXED program.










4.1 Review of the ECOG EST 1582 study
In this Chapter, we analyze the treatment effect of the ECOG EST 1582
data, using the unified parametric proportional hazards model and meta-analysis
model. The ECOG EST 1582 study, a multi-center clinical trial in small-cell
lung cancer, compares two different chemotherapy regimens: a standard therapy
consisting of cyclophosphamide, adriamycin and vincristine (CAV) and an alter-
nating regimen (CAV-HEM), where cycles of CAV were alternated with HEM
(hexamethylmelamine, etoposide and methotrexate). The primary end point is
patient death. In addition to the two treatment arms, there are four important
covariates that affected patient survival: presence or absence of bone metastases,
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presence or absence of liver metastases, performance status at study entry, and
weight loss prior to entry.
Gray [9] has made a detailed analysis of center variation in this data. He ex-
cluded centers contributing three or fewer patients, which left 570 patients from
26 centers, with the number of patients per center varying from 5 to 56 (me-
dian=18.5). In his analysis, he showed the presence of fixed treatment difference
between the CAV-HEM and the CAV arms across the participating centers and
discussed the possible causes for center variations in multi-center clinical trials.
Despite the tightly structured protocols, in multi-center clinical trials, center-
to-center variations can be caused by different standards of practice, types of
supportive care, interpretation of dose modifications, patient populations, and so
forth. He used a proportional hazards model shown in (4.1). let Xijk be covariate
k for subject j from center i, and in general assume g centers with ni cases from
center i, and p − 1 covariates, with Xij1 the treatment variable. A piecewise
constant model is used for the underlying hazard. Let 0 = t0 < t1 < . . . < tm be
the fixed boundaries of time intervals, and set Il(t) = I(tl−1 < t ≤ tl). Then, the
full model for the hazard for subject ij is










where the α = (α1, ..., αm)
′, β = (β1, ...βp)
′, ui and vi are unknown parameters,
and Xij = (Xijl, ...Xijp)
′. He used m = 30 intervals for the underlying hazard.
30
Gray [10] developed tests for group variation and showed that there is signif-
icant center variation among the treatment effects, but the variation among the
baseline hazards is not significant. This means that there is significant institu-
tional variation in patients’ survival in the CAV-HEM arm, but not in the CAV
arm.
4.2 Data analysis results
We fit unified parametric proportional hazards models discussed in Chap-
ter 2 and the meta-analysis models discussed in Chapter 3 to the 570 patient
dataset. For the unified proportional hazards model, we first fit three basic mod-
els and then tried other models with more parameters. The first three models are
a model with no random effect (model (2.3)), a model with center random effect
(model (2.8)), and a model with center and center-by-treatment random effects
(model (1.1)). To perform meta-analysis in this dataset, the following procedures
were used. First, to imitate the usual meta-analysis methods, we fit a paramet-
ric proportional hazards model (model (2.3)) for each center and collected the
log-hazard ratio and the standard error. Then, using the center estimates and
standard errors, we fit the random effect meta-analysis model (3.4).
Parameter estimates and standard errors of the three basic unified propor-
tional hazards model are shown in Table 4.1. Model 0 has the five covariate
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fixed effects but has no random effect. Model 1 has the five covariate effects
and a random center effect. The third model, Model 2, has the five covariate
fixed effects and two random effects, center and treatment-by-center interaction.
The log-hazard ratio of the CAV-HEM treatment relative to the HEM treatment
is −0.339 in model 0, −0.318 in model 1 and −0.332 in Model 2. This shows
that the treatment estimate of the fixed regression effect did not change substan-
tially after including the random effects. All four covariates in all three models
are statistically significant at the 0.05 level. Although standard errors for the
variance components are given, they should not be used directly to test against
zero by assuming normality, since the null hypothesis lies on the boundary of the
parameter space. The asymptotic null distribution of the change in deviance1 is
a mixture of χ21 and χ
2
0 with equal weights 0.5 [18, 19]. The χ
2
0 distribution is
the distribution which gives probability mass 1 to the value 0. If normality is
assumed for the change in deviance, the P -values would be overestimated and
the null hypothesis of no variance would be accepted too often. Here we look at
the magnitude of the change in deviance when we add the random effects in the
model. When center random effect is included (Model 1), the change in deviance
is only 3.2 (1105.0 − 1101.8) compared to Model 0. But when we include both
the center and the treatment-by-center random effects (Model 2), there is a sub-
stantial amount of change in the deviance (1101.8− 1081.1 = 20.7) compared to
1Deviance is defined as the log-liklihood multiplied by (-2). Note that, some authors use
”deviance” to refer to the difference between deviance of the original model and a reference
model.
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Table 4.1: Parameter estimates of the unified parametric proportional hazards
regression models for the ECOG EST 1582 data.
Model 0a Model 1b Model 2c
Estimate Estimate Estimate
Parameter (se) P-value (se) P-value (se) P-value
Scale 1.133 <.0001 1.271 <.0001 1.337 <.0001
(0.129) (0.040) (0.046)
Shape 1.244 <.0001 1.141 <.0001 1.129 <.0001
(0.037) (0.142) (0.144)
Treatment -0.339 0.0001 -0.318 0.0014 -0.332 0.0207
(0.087) (0.089) (0.134)
Bone 0.227 0.0155 0.241 0.0198 0.229 0.0300
(0.094) (0.097) (0.099)
Liver 0.293 0.0012 0.283 0.0050 0.293 0.0047
(0.090) (0.092) (0.094)
Perform -0.523 <.0001 -0.550 <.0001 -0.577 <.0001
(0.104) (0.107) (0.113)
Weight 0.230 0.0097 0.223 0.021 0.270 0.0075
(0.088) (0.091) (0.093)
σ2u - - 0.032 - 0.011 -
(0.026) (0.023)
σ2v - - - - 0.234 -
(0.109)
-2LogLik=1105.0 -2LogLik=1101.8 -2LogLik=1081.1
aModel 0 is a labeling for model (2.3).
bModel 1 is a labeling for model (2.8).
cModel 2 is a labeling for model (1.1).
Model 1, which indicates the importance of treatment-by-center random effect
in the model. Next, we fit other models with more parameters and look at the
change in the deviance. We consider Model 2 as our reference and compare the
change in deviance. The results are shown in Table 4.2. Each model in the table
has the treatment and the four fixed covariate effects. Model 3b, which is fit-
ted with the treatment and the four fixed covariate effects, center random effect,
treatment-by-center random effect and random bone effect has a deviance value
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of 1073.1, which is a change of 8 from Model 2. Model 5, which is fitted with
the treatment and the four covarite fixed effects, bone-by-treatment fixed effect,
center random effect, treatment-by-center random effect, and bone random effect
has a substantially smaller deviance from Model 2 (1081.1− 1069.6 = 11.5). As
shown in the table, the other models did not result in substantial change.
For the meta-analysis to have more data in each center, we decided to merge
Table 4.2: Proportional hazards regression and -2logLik values for ECOG data.
(Fixed=Treatment and the four covariate fixed effects, ui=center random ef-
fect, vi=treatment random effect, bi=bone random effect, li=liver random effect,
pi=performance random effect, wi=weight random effect)
# of
Model -2logLik parameters
Model 0: Fixed 1105.0 7
Model 1: Fixed+ui 1101.8 8
Model 2: Fixed+ui+vi 1081.1 9
Model 3b: Fixed+ui+vi+bi 1073.1 10
Model 3l: Fixed+ui+vi+li 1080.2 10
Model 3p: Fixed+ui+vi+pi 1081.1 10
Model 3w: Fixed+ui+vi+wi 1080.5 10
Model 4: Fixed+Bone*Treat+ui+vi 1077.0 10
Model 5: Fixed+Bone*Treat+ui+vi+bi 1069.6 11
some centers based on similarity of the unweighed center average of the covariates
(bone, liver, performance, weight) using a method of divisive hierarchical cluster-
ing. Divisive hierarchical clustering is a top-down clustering method which starts
with a single cluster containing all objects, and then successively splits resulting
clusters until only clusters of individual objects remain [20]. At each stage of the
divisive algorithm the cluster with the largest diameter that is available after the
previous step is selected for the next split. The diameter of a cluster is the largest
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dissimilarity between any two of its observations. Dissimilarities are calculated
using the Euclidean distances, which are the root sum-of-squares of differences.
To divide the selected cluster, the algorithm first looks for its most disparate
observation, that is, the observation which has the largest average dissimilarity
to the other observations of the selected cluster. This observation initiates a
new group (splinter group). In subsequent steps within the same splitting stage,
for each object of the old group we compute the average dissimilarity with the
remaining objects, and compare it to the average dissimilarity with the object
of the splinter group. The average dissimilarity of an object is the average dis-
similarity to all other objects in the group. The algorithm reassigns observations
that are closer to the splinter group than to the old group. The algorithm results
in a division of the selected cluster into two new clusters. We used the diana
function in the R cluster library, based on the center average vectors of the
four covariates from the 26 centers. That is, the data matrix used in diana is
organized in such a way that each row corresponds to a center, and each column
corresponds to a covariate average, where there are 26 rows and 4 columns. We
required each center to have at least 15 patients as a stopping criterion of the
splitting process.
We were left with 18 centers where the sample size varied from 17 to 56. A
proportional hazards model (2.3) on each center was fitted. The log-hazard ra-
tio and standard error estimates for a CAV-HEM treatment relative to the CAV
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treatment for each center were collected. Table 4.3 shows the treatment effect
estimates for each center, and Figure 4.2 shows the corresponding forest plot.
A forest plot is a graphical display designed to illustrate the relative strength
of treatment effects in multiple studies addressing the same question. In meta-
analysis forest plot is used as a means of graphically representing the results of
each trials (e.g. [4] and [13]). The left-hand column lists the names of the studies
and the right-hand column is a plot of the measure of effect (e.g. log hazard
ratio) for each of these studies incorporating confidence intervals represented by
horizontal lines. The measure of effects is often represented by square, and the
area of each square is proportional to the study’s weight in the meta-analysis.
A vertical line representing no effect is also plotted. If the confidence intervals
for individual studies overlap with this line, it indicates that at the given level
of confidence, their effect size do not differ significantly from no effect for the
individual study.
A negative estimate indicates that CAV-HEM treatment has a beneficial effect
in longer survival. Thirteen centers have negative estimates and the remaining
five centers have positive estimates. Four of the centers (7, 22, 25+41, and 26)
showed a statistically significant difference of the CAV-HEM treatments. In the
other fourteen centers there was no significant difference between the CAV-HEM
and HEM treatments. A random effect meta-analysis model (3.4) was fitted. A
restricted maximum likelihood (REML) estimate of −0.339 with standard error
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of 0.126 was obtained. This shows that the unified proportional hazards model
and the meta-analysis model give very similar estimates. The normality assump-
tion in the meta-analysis model was checked graphically. Histogram, Q-Q plot
and Empirical cumulative density function (CDF) plot, for the error terms based
on 18 error points, are shown in Figure 4.2. None of these plots show violation
of the normality assumption.
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Table 4.3: Estimates of the log hazard ratio for treatment in each center for
ECOG EST 1582 study
Study center # of patients θ̂i se(θ̂i) 95% CI
1 21 -1.018 0.569 (-2.133, 0.098)
5+59 17 -0.782 0.616 (-1.989, 0.425)
7 18 -1.717 0.615 (-2.921, -0.512)
10 27 -0.545 0.480 (-1.485, 0.395)
13 46 0.303 0.352 (-0.387, 0.993)
18+61 31 -0.529 0.383 (-1.280, 0.222)
19+21 28 0.022 0.448 (-0.856, 0.901)
20 48 -0.073 0.298 (-0.656, 0.510)
22 56 -0.696 0.318 (-1.319, -0.073)
25+41 31 -0.974 0.475 (-1.904, -0.044)
26 22 -1.085 0.493 (-2.050, -0.119)
28+52+60 39 -0.432 0.354 (-1.126, 0.262)
33 27 -0.394 0.450 (-1.276, 0.488)
36+51 53 0.405 0.323 (-0.227, 1.037)
38 17 -0.435 0.809 (-2.021, 1.151)
39+49 42 -0.056 0.352 (-0.747, 0.635)
40 23 0.144 0.540 (-0.914, 1.202)





























Figure 4.1: The log-hazard ratio for treatment with CAV-HEM relative to CAV.
The square shows a study estimate and the size is proportional to the inverse of

































































































(c) Empirical CDF plot.
Figure 4.2: Error plots of the ECOG EST 1582 data from meta-analysis based
on 18 residual error values.
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4.3 SAS statements for unified analysis
The SAS code for the proportional hazards model (1.1) in Chapter 1 with
Weibull baseline hazard rate (Model 2 in Table 4.2) is given below. The code for
the other models in Table 4.2 can be programmed with slight modification.
proc nlmixed data=ECOG;
parms alpha=1 lambda=1 Treatcoff=-1 Bonecoff=1 Livercoff=1






if status=0 then loglik=loglik0;
if status=1 then loglik=log(basehaz)+mureg+loglik0;
model Time~general(loglik);






A simulation study was carried out to compare the performance of the
unified approach (Chapter 2 ) and the meta-analysis approach (Chapter 3) in
estimating the treatment effect of a multi-center clinical trial study. True param-
eters for data simulation were considered in line with the ECOG EST 1582 data
used in the previous chapter. Data simulation was carried out in two steps. First,
center random effects (ui) and center-by-treatment interaction random effects (vi)
were generated independently from a normal distribution; i.e. ui ∼ N(0, σ2) and
vi ∼ N(0, τ 2). We varied σ2 to be 0.4 or 0.001 and τ 2 to be 0.3 or 0.16. Then
independent survival times Ti1, . . . , Ting were generated from a Weibull distribu-
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tion assuming the scale parameter λ = 2 and shape parameter ρ = 1.4. That
is, Tij = [−λ−1 log(aij)/ exp(
∑p
k=1Xijkβk + ui + viXij1)]
1/ρ where aij is a random
number generated from a uniform distribution U(0,1).
The number of centers (18) and the number of patients in each center was
taken to be equal to those in the clustered ECOG EST 1582 dataset. Therefore
the total number of patients is 570. We conducted the simulation study with
and without covariates. When covariates are present they are either taken from
the ECOG EST 1582 data or are simulated as independent and identically dis-
tributed binary variables with probability based on the design matrix explained
in the next paragraph and the data is generated with coefficients, βk, for bone,
liver, performance and weight fixed at β2 = 0.2, β3 = 0.3, β4 = −0.5 and β5 = 0.2
respectively. These coefficients in the simulation are fixed based on the coeffi-
cients found in the ECOG EST 1582 data.
We used four different design matrices and Xijk varies depending on the type
of design matrix specified. For each scenario a single design matrix was fixed at
the beginning of the simulation and used throughout the whole iteration. The
first design matrix is the ‘Original Design Matrix (ODM)’, where the ECOG EST
1582 data design matrix was used for both the covariates and treatment. This
means that each center in the simulation has exactly the same design matrix as
the corresponding center in ECOG EST 1582 data. According to ODM, for a case
j in center i in the simulation, the survival time is generated based on the Xij in
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the ECOG EST 1582 data and the aij are generated from a uniform distribution
U(0,1). The second design matrix is ‘Multinomial Design Matrix (MDM)’, where
for center i, the Xijk are randomly generated from Bernouilli distributions with
probability pik equal to the proportion of 1 for variable k in center i. In MDM
treatment assignment is also randomly generated from a Bernouilli distribution
with pi1 equal to the proportion of treated patients in center i. The third design
matrix is the ‘Uniform Design Matrix (UDM)’, which is similar to the the second
one, but the Xijk for each center are randomly generated with probability pk
equal to the overall proportions of 1 for variable k in the ECOG EST 1582 data.
Treatment assignment is also generated using probability p1, which is the overall
proportion of treated patients in the ECOG EST 1582 data. The fourth design
matrix is the ‘Absence of covariates Design Matrix (ADM),’ where covariates are
not included in the data generation and model fitting. The survival times were
generated from Tij = [−λ−1 log(aij)/ exp(Xij1β1 + ui + viXij1)]1/ρ. Treatment
assignment is taken from the ECOG EST 1582 data. ADM can be seen as the
original design matrix without covariates.
The simulation programs were written using SAS 9.1 and executed on the
SunOS 5.9 platform at the University of Maryland, College Park. The programs
are set up in a batch mode so that they can run to completion without human
interaction. We have experienced two main problems: First, the execution times
were very long. A single simulation scenario with 1000 iterations and all the
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four covariates included takes 14 to 18 hours. Second, the program receives a
terminating signal from an unknown source and stops running before it reaches
completion. In addition to these two main problems, we are unable to run more
than one program at a time. When two or more programs submitted at a time,
all programs stop before completing the full number of iterations. When the
programs stop running before they reach the specified number of iteration, we
re-run until we get the full iteration. Thus, all the simulation results in Section
5.2.1 are based on 1000 iteration and all the results in Section 5.2.2 are based on
500 iteration.
5.2 Results
The simulation results are organized in two sections, section I and sec-
tion II. The first section has results from the basic simulation and each simulation
is replicated 1000 times. Based on the findings in the first section, additional sim-
ulations were conducted, and results are presented in section II. In the second
Section, each simulation is replicated 500 times. In both sections, the unified pro-
portional hazards model (1.1) and random effects meta-analysis model (3.4) were
fitted. For meta-analysis, first a parametric proportional hazards model without
random effect (2.5) was fitted for each center. Then, the log hazard ratio and
standard error from each center were collected and used to fit the random effect
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meta-analysis model. For each simulation scenario, the mean, the median, the
root mean squared error (RMSE) of β̂1, and the percentage of the models with
significant treatment effect were collected and tabulated for both models. The
percentage of the models with significant treatment effect was calculated as the
proportion of simulation runs in which the upper bound of the 95% confidence
interval of the log-hazard ratio was less than zero. Significant treatment effects
always occurred with negative log hazard ratios.
5.2.1 Section I: Basic simulation
The results of the simulation studies using a unified model and meta-analysis
model are summarized in Table 5.1 – Table 5.4. In general, the log-hazard ratio
of treatment (β1) is estimated well in both the unified and meta-analysis models
for all design matrices. The results from the original design matrix are tabu-
lated in Table 5.1. The unified model estimates the log-hazard ratio of treatment
with negligible error; however, the meta-analysis model overestimates the treat-
ment effect, and the variability of β1, as measured by root mean square error
(RMSE), is higher when compared to the unified model. The percentage of a
significant treatment effect in meta-analysis is less than the percentage of a sig-
nificant treatment effect in the unified analysis. For both methods, when the
variance of treatment-by-center random effect is fixed higher in the data simula-
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tion, the percentage of significance decreases as compared when the variance is
fixed lower. For example, consider the case where the true value of β1 is −0.4
and var(ui) is 0.3; when var(vi) is 0.3, the unified and meta-analysis models have
significant treatment effects 68.4% and 66.2% of the time respectively; whereas,
when var(vi) is 0.16, the unified and meta-analysis models have significant treat-
ment effects 86.8% and 80.4% of the time respectively. The results from the
multinomial design matrix are similar to the results with the original design ma-
trix. The results are tabulated in Table 5.2.
The results of the UDM are displayed in Table 5.3. With the UDM the bias
and RMSE are similar as in the cases with ODM and MDM. However, the per-
centage of a significant treatment effect in the meta-analysis is comparable to the
unified analysis.
The results in ADM are shown in Table 5.4. The results both from the unified
and meta-analysis models are similar by all criteria we compared. In both mod-
els, the treatment effect is estimated with negligible bias and with similar RMSE.
The percentage of significant treatment effects is also similar in both models.
The significance of bias of β̂1 can be tested by constructing a 95% CI for β1
as β̂1 ± (RMSE/
√
R × 1.96), where R is the number of simulation iterations
(1000 or 500). We constructed this confidence interval in Table 5.1 under the
unified analysis, and only the first row has shown a significant bias. Under the
meta-analysis all the estimated β̂1 values are clearly significantly biased. For the
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rest of the simulation tables, the bias of β̂1 can be tested similarly.
The magnitude and direction of the biases of the estimate are shown graph-
ically in Figures 5.1 and 5.2 when the true values are β1 = −0.4, var(ui) = 0.4
and var(vi) = 0.3 under each design matrix. The estimated treatment effect, β̂1,
values are shown by the vertical broken lines.
5.2.2 Section II: Additional simulation
In each of the additional simulations below, we fit the same unified analysis
model (1.1) and random effect meta-analysis model (3.4) while varying the way
the data is generated. From Section I, we have seen that when the covariates
are not included, the estimates both from the unified and meta-analysis models
are unbiased. However, when the covariates are included, bias is introduced in
the meta-analysis estimate. Based on this initial result, we further investigated
the relationship between the number of covariates and the magnitude of the bias.
We conducted simulation studies in the presence of only one covariate (liver) and
two covariates (liver and weight) under MDM and UDM. The results are shown
in Table 5.5. The results show that as the number of covariates increase the bias
in the meta-analysis estimate increases.
Treatment effect estimates, when there are one, two, and four covariates, were
collected from the previous tables and displayed together in Table 5.6. We dis-
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played this table for the purpose of convenience to look at the association between
the number of covariates and the bias in one place.
In addition to the simulation scenarios discussed above, we conducted a com-
parison of the two methods by generating data with random terms in each co-
variate. The random terms generated independent of each other from a normal
distribution with mean zero and variance 0.4, 0.3, 0.1 and 0.24 for bone, liver,
performance, and weight respectively. This is a scenario in which we were fitting
a misspecified model. The results are displayed in Table 5.7. The presence of
random effects on covariates create bias in the unified analysis, where treatment
effects are underestimated. The meta-analysis estimates appear unaffected and
remain with the same magnitude and direction of bias as in section I.
Finally we simulated data with the four fixed effects, treatment fixed effect,
center and treatment-by-center random effects, and bone-by-treatment random
effect. The random term for the bone-by-treatment interaction is generated from
a normal distribution with mean zero and variance 0.2. Multinomial and uniform
design matrices used. The results are displayed in Table 5.8. Both unified and
meta-analysis results are similar to the results in Section I.
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Table 5.1: Simulation results with original design matrix from unified regres-
sion analysis and meta-analysis. (In the table, Unf=Unified regression, and
Meta=Meta-analysis regression)
True Parameters Estimated values
β̂1 % of sig.
(RMSE) Median Effect
β1 σ
2 τ 2 Unf Meta Unf Meta Unf Meta
-0.4 0.4 0.3 -0.412a -0.456 -0.405 -0.451 68.4 66.2
(0.161) (0.197)
-0.4 0.4 0.16 -0.398 -0.447 -0.399 -0.445 86.8 80.4
(0.126) (0.164)
-0.4 0.001 0.3 -0.407 -0.452 -0.405 -0.452 71.5 64.3
(0.161) (0.202)
-0.4 0.001 0.16 -0.404 -0.450 -0.405 -0.450 88.7 81.2
(0.130) (0.167)
-0.2 0.4 0.3 -0.206 -0.229 -0.215 -0.233 21.9 23.3
(0.253) (0.261)
-0.2 0.4 0.16 -0.197 -0.223 -0.200 -0.228 34.6 27.5
(0.126) (0.155)
-0.2 0.001 0.3 -0.202 -0.231 -0.207 -0.226 28.9 24.0
(0.158) (0.190)
-0.2 0.001 0.16 -0.206 -0.227 -0.203 -0.225 41.3 35.2
(0.122) (0.155)
aThis single β̂1 is significantly biased. The 95% CI is (−0.422,−0.402), which does not
include the true value of β1 = −0.4.
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Table 5.2: Simulation results with multinomial design matrix from unified regres-
sion analysis and meta-analysis
True Parameters Estimated values
β̂1 % of sig.
(RMSE) Median Effect
β1 σ
2 τ 2 Unf Meta Unf Meta Unf Meta
-0.4 0.4 0.3 -0.408 -0.447 -0.409 -0.446 65.4 60.2
(0.161) (0.205)
-0.4 0.4 0.16 -0.411 -0.450 -0.413 -0.453 84.1 76.6
(0.134) (0.173)
-0.4 0.001 0.3 -0.409 -0.446 -0.412 -0.442 73.3 62.0
(0.158) (0.205)
-0.4 0.001 0.16 -0.406 -0.449 -0.403 -0.450 87.4 77.8
(0.130) (0.170)
-0.2 0.4 0.3 -0.200 -0.221 -0.199 -0.223 27.7 21.9
(0.161) (0.202)
-0.2 0.4 0.16 -0.197 -0.223 -0.200 -0.228 34.6 27.5
(0.126) (0.155)
-0.2 0.001 0.3 -0.206 -0.224 -0.206 -0.218 29.8 23.0
(0.158) (0.195)
-0.2 0.001 0.16 -0.201 -0.212 -0.198 -0.214 32.5 25.5
(0.134) (0.170)
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Table 5.3: Simulation results with uniform design matrix from unified regression
analysis and meta-analysis
True Parameters Estimated values
β̂1 % of sig.
(RMSE) Median Effect
β1 σ
2 τ 2 Unf Meta Unf Meta Unf Meta
-0.4 0.4 0.3 -0.409 -0.461 -0.406 -0.452 64.6 64.4
(0.161) (0.197)
-0.4 0.4 0.16 -0.411 -0.450 -0.413 -0.453 84.1 76.6
(0.134) (0.173)
-0.4 0.001 0.3 -0.405 -0.465 -0.408 -0.461 71.9 76.6
(0.154) (0.205)
-0.4 0.001 0.16 -0.406 -0.461 -0.406 -0.460 85.5 78.8
(0.138) (0.179)
-0.2 0.4 0.3 -0.215 -0.245 -0.216 -0.246 23.6 25.0
(0.245) (0.249)
-0.2 0.4 0.16 -0.199 -0.225 -0.197 -0.222 36.2 30.2
(0.130) (0.164)
-0.2 0.001 0.3 -0.208 -0.241 -0.214 -0.242 25.5 24.3
(0.249) (0.253)
-0.2 0.001 0.16 -0.215 -0.250 -0.219 -0.246 38.6 36.7
(0.134) (0.176)
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Table 5.4: Simulation results with Absence of Covariate Design Matrix from
unified regression analysis and meta-analysis
True Parameters Estimated values
β̂1 % of sig.
(RMSE) Median Effect
β1 σ
2 τ 2 Unf Meta Unf Meta Unf Meta
-0.4 0.4 0.3 -0.406 -0.406 -0.407 -0.411 66.9 69.9
(0.161) (0.167)
-0.4 0.4 0.16 -0.408 -0.404 -0.409 -0.407 82.2 83.5
(0.134) (0.138)
-0.4 0.001 0.3 -0.406 -0.411 -0.407 -0.413 75.1 69.7
(0.155) (0.164)
-0.4 0.001 0.16 -0.399 -0.403 -0.396 -0.399 88.5 86.1
(0.126) (0.130)
-0.2 0.4 0.3 -0.203 -0.200 -0.201 -0.194 22.1 23.8
(0.251) (0.259)
-0.2 0.4 0.16 -0.205 -0.199 -0.210 -0.205 31.3 32.5
(0.235) (0.241)
-0.2 0.001 0.30 -0.201 -0.198 -0.203 -0.204 24.9 24.0
(0.253) (0.261)









































































Figure 5.1: Histogram for simulation results of the log-hazard ratio for ODM and
MDM. In both cases the data is generated with true values β1 = −0.4, σ2 = 0.4







































































(d) No Cov Meta-analysis.
Figure 5.2: Histogram for simulation results of the log-hazard ratio for UDM and
No Cov. In both cases the data is generated with true values β1 = −0.4, σ2 = 0.4
and τ 2 = 0.3. The vertical broken line shows the estimated log hazard ratio β̂1.
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Table 5.5: Parameter estimates from unified regression and meta-analysis with
one and two covariates with varying design matrices.
True Parameters Estimated values
β̂1 % of sig.
Design (RMSE) Median Effect
Mtrx β1 σ
2 τ 2 Unf Meta Unf Meta Unf Meta
One Covariate
UDM -0.4 0.001 0.3 -0.398 -0.409 -0.400 -0.406 72.6 66.6
(0.158) (0.176)
-0.2 0.4 0.16 -0.193 -0.195 -0.193 -0.190 33.2 29.0
(0.134) (0.141)
MDM -0.4 0.001 0.3 -0.402 -0.415 -0.398 -0.405 74.2 67.0
(0.155) (0.167)
-0.2 0.4 0.16 -0.201 -0.218 -0.206 -0.227 39.6 36.2
(0.138) (0.148)
Two Covariates
UDM -0.4 0.001 0.3 -0.417 -0.453 -0.423 -0.458 77.0 73.6
(0.155) (0.182)
-0.2 0.4 0.16 -0.192 -0.202 -0.201 -0.197 37.0 30.6
(0.130) (0.148)
MDM -0.4 0.001 0.3 -0.411 -0.431 -0.424 -0.440 75.6 67.8
(0.158) (0.179)
-0.2 0.4 0.16 -0.202 -0.213 -0.200 -0.212 36.0 28.8
(0.130) (0.148)




2 τ 2 1 Cov 2 Cov 4 Cov
MDM -0.4 0.001 0.3 0.013 0.020 0.037
-0.2 0.4 0.16 0.017 0.011 0.026
UDM -0.4 0.001 0.3 0.011 0.036 0.060
-0.2 0.4 0.16 0.002 0.010 0.026
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Table 5.7: Parameter estimates from unified regression and meta-analysis. Data
generated including both fixed and all covariates random effect.
True Parameters Estimated values
β̂1 % of sig.
Design (RMSE) Median Effect
Mtrx β1 σ
2 τ 2 Unf Meta Unf Meta Unf Meta
UDM -0.4 0.4 0.3 -0.369 -0.470 -0.364 -0.475 64.20 65.6
(0.161) (0.212)
-0.2 0.001 0.3 -0.182 -0.243 -0.191 -0.240 26.00 26.5
(0.158) (0.205)
MDM -0.4 0.4 0.16 -0.361 -0.446 -0.364 -0.453 82.4 76.40
(0.134) (0.173)
-0.2 0.001 0.3 -0.176 -0.213 -0.176 -0.217 26.00 20.8
(0.158) (0.200)
Table 5.8: Parameter estimates from unified regression and meta-analysis. Data
generated with all covariates fixed effect, treatment fixed effect, center and
treatment-by-center random effects, and bone-by-treatment random effects.
True Parameters Estimated values
β̂1 Treatment
Design (RMSE) Median Effect(%)
Mtrx β1 σ
2 τ 2 Unf Meta Unf Meta Unf Meta
UDM -0.4 0.001 0.3 -0.401 -0.445 -0.398 -0.437 73.4 61.8
(0.158) (0.200)
-0.2 0.4 0.16 -0.213 -0.233 -0.218 -0.244 40.6 31.8
(0.141) (0.176)
MDM -0.4 0.001 0.3 -0.425 -0.443 -0.421 -0.442 76.4 63.3
(0.161) (0.197)





In this thesis we conducted data analysis and a simulation study in a multi-
center clinical trial setting. The data that was used (ECOG EST 1582) comes
from a multi-center clinical trial study where previous studies have shown the
treatment effect to vary by center [9, 10]. The simulation study is conducted by
varying parameters in models and designs chosen for similarity with the ECOG
EST 1582 data.
The main goal of our research has been to evaluate meta-analysis treatment
effect estimates by using a patient level data from a multi-center clinical trial
study. Both on the real and simulated dataset we performed a unified analysis
using the patient level data, and a meta-analysis using a summary information
obtained from each center. In the meta-analysis, to imitate the usual practice,
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we took the summary information from each center that might be published in
a journal article and estimated overall treatment effect using meta-analysis. The
estimates from the unified analysis and meta-analysis are compared in terms of
bias, RMSE, and percentage of significant treatment effect.
For the unified analysis, we used a parametric proportional hazards model
with Weibull baseline hazard. The model is fitted by likelihood methods using
a numerical integration of the random effects via Gaussian quadrature, which is
implemented in SAS NLMIXED procedure [14, 15]. For meta-analysis, the ran-
dom effect meta-analysis model is used and REML estimates obtained using the
PROC MIXED procedure in SAS.
Our simulation study has shown that under certain conditions (when covari-
ates are included), meta-analysis yields slightly biased estimates for the overall
treatment effect. The simulation study also showed, surprisingly, that the mag-
nitude of the bias is directly related to the number of covariates. The reasons for
this relationship between the covariates and magnitude of the bias is not known
and needs further investigation. In all the scenarios we considered, when bias
was present, the meta-analysis overestimated the treatment effect. If the bias
had resulted in an underestimate of the treatment effect, it would have been
more dangerous because of a tendency to incorrect hypothesis outcomes.
In the data analysis, we conducted the unified analysis and the meta-analysis
on the ECOG EST 1582 data. The center level analysis shows that there is a
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great variation in treatment effect between the centers; only a few centers have
statistically significant treatment effect and some centers even have a positive
point estimate although it is not statistically significant. But the overall treat-
ment effect estimates from the unified analysis and the meta-analysis are very
similar.
Based on our findings the following areas need further study: first, in our
simulation study we only considered a few scenarios. It is difficult to make a gen-
eral conclusion about the relationship of covariates and bias at this point. More
thorough simulation studies could explore different conditions. For example, what
will happen to the treatment estimates if the center and treatment-by-center ran-
dom effects are correlated? How would the direction and the magnitude of the
bias change if we choose different values for the center and treatment-by-center
variance than we considered here when we generate the data? In this paper,
we choose the center random effect variance as 0.001 or 0.4, and the treatment-
by-center random effect variance as 0.16 or 0.3. Second, the simulation analysis
performed in this thesis is not a theoretical proof. Thus, a theoretical explanation
for the relation between the covariates and the bias needs to be conducted.
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